NCT07373990 2026-01-28
Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
Clinical Trials
13 trialsNCT06914011 2025-12-03
MRD2START
Asan Medical Center
Phase 3 Not yet recruiting
NCT07132008 2025-08-20
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
First Affiliated Hospital of Guangxi Medical University
Phase 3 Not yet recruiting
NCT07068516 2025-07-16
Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer
Zhejiang Cancer Hospital
Phase 3 Not yet recruiting
NCT06598527 2025-05-29
SACTION2401
Sun Yat-sen University
Phase 3 Recruiting
NCT06332274 2025-05-13
UMBRELLA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT06258811 2025-03-13
Neoadjuvant Immunochemotherapy for LAOSCC
Huashan Hospital
Phase 3 Recruiting
NCT06704620 2024-12-16
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting
NCT06520683 2024-11-07
SMALLER
Sun Yat-sen University
Phase 3 Recruiting
NCT06383780 2024-07-16
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.
Sun Yat-sen University
Phase 3 Recruiting
NCT06441110 2024-06-04
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Fujian Medical University Union Hospital
Phase 3 Recruiting
NCT05211232 2024-04-18
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Active not recruiting
NCT05342792 2022-04-25
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting